Monika Paluszewska

Suggest Changes
Learn More
Patients with Philadelphia chromosome-positive (Ph+) and/or BCR–ABL+ acute lymphoblastic leukemia (ALL) have extremely poor prognoses. Most of these patients have additional, heterogenous karyotype(More)
The treatment of adults with Philadelphia-negative acute lymphoblastic leukaemia (ALL) depends on the presence of risk factors including age, white blood cell count, immunophenotype and time to(More)
To assess the efficacy of an original DAC-7 regimen: daunorubicine (DNR) 60 mg/m2/day, days 1–3; cytarabine (AraC) 200 mg/m2/day, days 1–7; cladribine (2-CdA) 5 mg/m2/day, days 1–5, 400 untreated(More)
Sixty-four untreated adult acute lymphoblastic leukemia (ALL) patients were randomized to receive chemotherapy alone, n = 31 or chemotherapy and granulocyte colony stimulating factor (G-CSF), n = 33.(More)
Fms-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) and mixed-lineage leukemia gene–partial tandem duplication (MLL-PTD) are aberrations associated with leukemia which indicate(More)
Approximately one third of multiple myeloma patients (below 60 years) are diagnosed either in advanced disease or with significant comorbidities. Many other patients referred to transplant centers(More)